Theranos ends clinical work, shifts focus to selling diagnostic device
OCT 06, 2016
DOI: 10.1063/PT.5.0210142
Ars Technica : On 5 October Theranos CEO and founder Elizabeth Holmes released an open letter announcing that the troubled blood-testing company was restructuring to focus on selling diagnostic equipment. The company will lay off about 340 employees and close its labs and wellness centers. Theranos had built its reputation on the ability to run a wide variety of tests on a relatively small blood sample, but its Edison device has been shown to be inaccurate and unreliable. In July, federal regulators revoked the company’s license to perform clinical lab work.
© 2016 American Institute of Physics
